BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang P, Qin C, Liu N, Zhou X, Chu X, Lv F, Gu Y, Yin L, Liu J, Zhou J, Huo M. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang H, Xue M, Su P, Zhou Y, Li X, Li Z, Xia Y, Zhang C, Fu M, Zheng X, Luo G, Wei T, Wang X, Ding Y, Zhu J, Zhuang T. RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast Cancer. J Exp Clin Cancer Res 2022;41:364. [PMID: 36581998 DOI: 10.1186/s13046-022-02576-y] [Reference Citation Analysis]
2 Ali R, Shao H, Varamini P. Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations. Pharmaceutics 2022;15. [PMID: 36678741 DOI: 10.3390/pharmaceutics15010112] [Reference Citation Analysis]
3 Yan Tie, Fan Tang, Dandan Peng, Ye Zhang, Huashan Shi. TGF-beta signal transduction: biology, function and therapy for diseases. Mol Biomed 2022;3:45. [PMID: 36534225 DOI: 10.1186/s43556-022-00109-9] [Reference Citation Analysis]
4 Wu H, Wei G, Luo L, Li L, Gao Y, Tan X, Wang S, Chang H, Liu Y, Wei Y, Song J, Zhang Z, Huo J. Ginsenoside Rg3 nanoparticles with permeation enhancing based chitosan derivatives were encapsulated with doxorubicin by thermosensitive hydrogel and anti-cancer evaluation of peritumoral hydrogel injection combined with PD-L1 antibody. Biomater Res 2022;26:77. [PMID: 36494759 DOI: 10.1186/s40824-022-00329-8] [Reference Citation Analysis]
5 Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, Zhou P, Dai Z, Wu K. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer 2022;10. [PMID: 36460337 DOI: 10.1136/jitc-2022-005543] [Reference Citation Analysis]
6 Li X, Ma S, Gao T, Mai Y, Song Z, Yang J. The main battlefield of mRNA vaccine – Tumor immune microenvironment. International Immunopharmacology 2022;113:109367. [DOI: 10.1016/j.intimp.2022.109367] [Reference Citation Analysis]
7 Gadi V, Gupta D, Shetty S. Emerging Potentials of Nanotherapeutics in Breast Cancer Microenvironment Targeting. OpenNano 2022. [DOI: 10.1016/j.onano.2022.100101] [Reference Citation Analysis]
8 Ma S, Zhang N, Hou J, Liu S, Wang J, Lu B, Zhu F, Wei P, Hong G, Liu T. Synthesis and Discovery of Ligustrazine–Heterocycle Derivatives as Antitumor Agents. Front Chem 2022;10:941367. [DOI: 10.3389/fchem.2022.941367] [Reference Citation Analysis]